Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Moderna Chairman Noubar Afeyan says the trial results remind him of when his company developed its Covid-19 vaccine.

The company says a trial met its goal to prevent melanoma recurrence.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

Moderna shares soared 172% after strong results for its vaccine for melanoma skin cancer. Elsewhere, the Evergrande saga came ...

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

By Michael Erman and Julie Steenhuysen Aug 19 (Reuters) - Moderna and Merck said on Wednesday that a personalized mRNA cancer ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...